Search results
Results from the WOW.Com Content Network
Pseudobulbar affect (PBA), or emotional incontinence, is a type of neurological disorder characterized by uncontrollable episodes of crying or laughing. PBA occurs secondary to a neurologic disorder or brain injury. Patients may find themselves crying uncontrollably at something that is only slightly sad, being unable to stop themselves for ...
Since pseudobulbar palsy is a syndrome associated with other diseases, treating the underlying disease may eventually reduce the symptoms of pseudobulbar palsy. [ citation needed ] Possible pharmacological interventions for pseudobulbar affect include the tricyclic antidepressants , serotonin reuptake inhibitors , and a novel approach utilizing ...
It has one drug currently approved by the Food and Drug Administration, Nuedexta, for the treatment of pseudobulbar affect. Avanir Pharmaceuticals (NAS: AVNR) is a biotechnology company developing ...
Paradoxical laughter has been consistently identified as a recurring emotional-cognitive symptom in schizophrenia diagnosis. Closely linked to paradoxical laughter is the symptom; inappropriate affect, defined by the APA Dictionary of Psychology as "emotional responses that are not in keeping with the situation or are incompatible with expressed thoughts or wishes". [3]
The growth continues for biopharmaceutical company Avanir Pharmaceuticals , which reported its 10th consecutive quarter of double-digit revenue growth despite widening losses for the quarter. For ...
Avanir Pharmaceuticals' (NAS: AVNR) first full quarter marketing Nuedexta was only marginally better than the quarter it launched in. Net sales of Neudexta were just $1.9 million, which is an ...
DXM/quinidine is used in the treatment of PBA. In a 12-week randomized, double-blind trial, amyotrophic lateral sclerosis and multiple sclerosis patients with significant PBA were given either Nuedexta 20/10 mg or placebo.
Avanir Pharmaceuticals , a biopharmaceutical company focused on developing therapies to treat central nervous system disorders, reported strong product sales growth in its first-quarter earnings ...